Sentences with phrase «lymphocytic leukemia»
Lymphocytic leukemia is a type of cancer that affects a specific kind of white blood cell called lymphocytes. These cells, which help to fight infections, grow abnormally and multiply too quickly, crowding out healthy blood cells in the bone marrow. This can weaken the immune system and make it harder for the body to fight off infections. Full definition
If chronic lymphocytic leukemia patients with a good or poor prognosis could be identified already at the time of diagnosis, physicians would have better possibilities to adjust their therapeutic and follow - up strategies.
scilifelab.se
Dr. Vines is frequently analyzing models used to understand how CCR7 affects the movement of breast cancer cells and T cell acute lymphocytic leukemia cells.
No improvement in long - term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets # 1 and # 2 treated with chemo (immuno) therapy
Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.
Examples of conditions the drug may be used for include lymphocytic leukemia, multiple myeloma, glomerulonephritis, non-erosive arthritis, immune - mediated skin disease, feline pemphigus foliaceous and severe feline eosinophilic granuloma complex.
List of abbreviations CNS: Central nervous system WHO: World Health Organization NF2: Neurofibromatosis 2 MA: Meningioangiomatosis ECOG: Eastern cooperative oncology group ALL: Acute lymphocytic leukemia CSF: Cerebrospinal fluid RIM: Radiation - induced meningiomas FISH: Fluoroscence in - situ hybridization CT: Computed tomography MRI: Magnetic resonance imaging
Venetoclax has durable clinical activity in patients with relapsed / refractory chronic lymphocytic leukemia whose disease progressed during or after ibrutinib therapy.
Jimenez de Oya N *, De Giovanni M *, Fioravanti J, Ubelhart R, Di Lucia P, Fiocchi A, Iacovelli S, Efremov DG, Caligaris - Cappio F, Jumaa H, Ghia P, Guidotti LG, Iannacone M. Pathogen - specific B cell receptors drive chronic lymphocytic leukemia by light chain - dependent cross-reaction with autoantigens.
Aggressive T - cell large granular lymphocytic leukemia (T - LGL) is a rare entity with a poor prognosis, the main clinical findings being splenomegaly, lymphadenopathy, thrombocytopenia and a CD3 + / CD56 + phenotype.
As chronic lymphocytic leukemia progresses slowly, some dogs can go on without chemotherapy for up to 2 years.
With bouts of arthritis, «The Biggest Kitty in the World» was successfully treated for Lymphocytic Leukemia at 13 (human) years old.
Lymphoma / lymphosarcoma or lymphocytic leukemia cancers can make total lymphocytes counts go both up or down.
To examine cancer - specific stress at treatment initiation as a predictor of psychological and physical functioning trajectories in patients with relapsed / refractory chronic lymphocytic leukemia during the first 5 months of treatment.
Their grassroots efforts, led initially by a local mother whose son was diagnosed with acute lymphocytic leukemia, reminded Brown of the community effort at New York's Love Canal, whose residents, having assessed their own chemical contamination, challenged the government and the corporations they held responsible.
The assessment of TP53 mutational status is becoming a routine clinical practice for chronic lymphocytic leukemia patients (CLL).
Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells.
Researchers will identify potential treatment targets for B - cell chronic lymphocytic leukemia in dogs and ways to identify high - risk patients.
A series of preliminary Mayo Clinic studies conducted in 2010 showed promise for the potential use of a chemical component of green tea (epigallocatechin gallate) in reducing the number of cancer cells in patients with chronic lymphocytic leukemia.
In particular, it is working on two drugs that target blood cancer therapies for non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
The drug treats chronic lymphocytic leukemia (CLL) and the drug is showing promise of moving up the treatment line to a front - line position where the market potential is even larger.
The risk for acute lymphocytic leukemia, lymphoma, and brain cancer is highest for children whose fathers have been heavy smokers for long periods of time.
Also benefitting will be The Leukemia & Lymphoma Society's Team in Training Program in memory of Jacquie Hirsch, a Williamsville native who lost her life to A.L.L. (Acute Lymphocytic Leukemia) September 6, 2008.
However, chronic lymphocytic leukemia (CLL), which is more common in the elderly, is difficult to cure, although long - term survival has been achieved in chronic myeloid leukemia due to the introduction of tyrosine kinase inhibitors (drugs that block signals promoting cancer cell growth).
In addition to ALL, asparaginase is also used to treat rarer cancers such as lymphosarcoma, Hodgkin's disease, chronic lymphocytic leukemia, reticulosarcoma and melanosarcoma.
About 10 percent of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase (BTK) inhibitor drug ibrutinib because of disease progression during clinical trials, according to a study published online by JAMA Oncology.
Combining the kinase inhibitor ibrutinib with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high - risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman School of Medicine at the University of Pennsylvania and Penn's Abramson Cancer Center (ACC).
Lymphoid cancers include diffuse large B - cell lymphomas (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL), which were the focus of the present study.
«Reasons for ibrutinib therapy discontinuation in patients with chronic lymphocytic leukemia.»
Ibrutinib has been approved by the U.S. Food and Drug Administration for the treatment of certain patients with several other cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström macroglobulinemia.
Auranofin is now in clinical trials for treating chronic lymphocytic leukemia.
By employing a translational approach and utilizing cutting - edge molecular tools, his research group has made outstanding contributions to our understanding of the mechanisms behind the development of chronic lymphocytic leukemia (CLL), the most common adult leukemia.
The authors conclude that FL118 - based therapy may be beneficial for a subgroup of cancer patients with tumors such as chronic lymphocytic leukemia and melanomas, in which MdmX overexpression confers treatment resistance.
A year later, Carlo Croce, now director of the Human Cancer Genetics Program at Ohio State University, reported that chronic lymphocytic leukemia (CLL), the most common form of the disease, was caused by deletion of two microRNA genes.
«We have seen SF3B1 mutation in chronic lymphocytic leukemia and in myeloid dysplastic disorders, and now we show its importance in mucosal melanoma,» says Aik Choon Tan, PhD, investigator at the CU Cancer Center and associate professor of Bioinformatics at the CU School of Medicine.
Patients who have enrolled in trials of this approach for acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL) typically undergo lymphodepleting chemotherapy before receiving an infusion of their newly engineered cells.
The new drug will now be tested in patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma in an early stage clinical trial.
The findings will be presented by Stephen Schuster, MD, the Robert and Margarita Louis - Dreyfus Associate Professor in Chronic Lymphocytic Leukemia and Lymphoma Clinical Care and Research in the Abramson Cancer Center.
In a dose - optimization study of 35 patients with chronic lymphocytic leukemia (CLL), researchers examined two different doses of CTL019 — a lower dose (5 x 107 cells) and a higher dose (5 x 108 cells).
Notch is one of the most frequently mutated genes in chronic lymphocytic leukemia (CLL), the most common leukemia in adults in the United States.
Some other lncRNAs have been found at higher levels in breast, stomach, lung, prostate cancer and chronic lymphocytic leukemia.
Levine and his colleagues designed a new gene that can be inserted into T cells to trick them into attacking cancerous B cells, the cause of chronic lymphocytic leukemia (CLL).
A Phase 1b, Open - Label, Dose Escalation Study of ME - 401 in Subjects with Relapsed / Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL / SLL) or Follicular Lymphoma (FL)
The FDA approved blinatumomab (Blincyto), an anti-CD19 targeted antibody, for the relapsed or refractory B - cell acute lymphocytic leukemia (ALL).
Auranofin is being evaluated by The Learning Collaborative as a treatment for relapsed chronic lymphocytic leukemia (CLL).
Chronic lymphocytic leukemia (CLL) is a malignancy characterized by the progressive accumulation of mature B cells.